Insulin cost cap kicks in across US, providing relief for some diabetics

WASHINGTON: Ms Kimberly Cavanaugh, who was diagnosed with Type 1 diabetes at the age of 14, has at times struggled to afford the costly insulin she needs and resorted to rationing her doses just to survive. 

“It was costing me, for a 30-day supply, between US$500 and close to US$900 just to refill one prescription. Now, I take two different types of insulin. So that’s going to be close to US$1,500 a month,” she said. 

However, the practice of rationing her supply has left her with long-term health issues.

“It should never be a choice between eating dinner or taking your insulin. I think with something like diabetes, there’s no grey area. It’s black and white,” said Ms Cavanaugh, adding that she has not always qualified for health insurance. “You can’t live without it and you have to take it.”

Now, some Americans living with diabetes will no longer need to ration or skip their insulin doses because of costs. 

CAPPING INSULIN PRICES

A new law which kicked in on Tuesday (Jan 3) will cap prices across the United States. 

About 3.3 million people with diabetes on one of the government’s Medicare plans will see the price of their Insulin capped at a maximum cost of US$35 per month.

It is part of the Inflation Reduction Act signed into law by President Joe Biden last August. The Act aims to, among other things, reduce the cost of medication.

This comes as insulin prices in the US have risen every year, for nearly two decades.

For instance, one vial of Humalog insulin now costs around US$330, up from US$21 in 1999.  

A new study has found that price hikes like this have led more than a million Americans to ration their supply.

This means they take just enough insulin to stay alive, but not enough to keep them healthy.

The Centers for Disease Control and Prevention estimates that more than 37 million Americans now live with diabetes. But that number is rising at an alarming rate as the population ages.

For all the latest world News Click Here 

Read original article here

Denial of responsibility! TechAI is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.